Stanozolol
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Stanozolol: Serpinopathy with toxic serpin polymerization
One-Sentence Summary
Stanozolol is a synthetic anabolic-androgenic steroid that is marketed in India as oral and injectable products. The TxGNN model predicts it may be relevant to serpinopathy with toxic serpin polymerization, but no clinical trials and no publications currently support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Serpinopathy with toxic serpin polymerization |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (10 of 10) – CDSCO approval status is not included in this data |
| Number of Listed Products | 10 (valid: 10) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for stanozolol are not available. Based on its drug class, stanozolol is an androgen receptor agonist that changes gene expression in the liver. It could therefore alter the production of hepatic serpin proteins. That is the only conceivable link to this disease.
This link is speculative and may even point the wrong way. In toxic polymerization disorders, such as alpha-1 antitrypsin deficiency, higher expression of a mutant serpin could worsen aggregation and liver injury. The high model score has no supporting trial or publication, so it should be treated as a hypothesis for laboratory investigation, not as a treatment signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Stanozolol is marketed in India, and all of the single-ingredient licences in the local data are valid. The list below shows five of them. Approved-indication text is not recorded in the local data.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 217404 | Tanzol 2mg Capsule | Strip of 10 capsules | Not stated in the licence record |
| 203547 | Stenfil 2mg Tablet | Strip of 10 tablets | Not stated in the licence record |
| 96382 | Ganzol 2mg Tablet | Strip of 10 tablets | Not stated in the licence record |
| 201784 | Stazol 50 Injection | Ampoule of 1 ml injection | Not stated in the licence record |
| 150720 | Neurabol Capsule | Strip of 10 capsules | Not stated in the licence record |
Safety Considerations
- Disease conditions flagged as contraindications (from the data compiled for this report, not from label text): kidney disease, liver disease, gallbladder disease, nephrotic syndrome, diabetes mellitus and diabetic ketoacidosis, benign prostatic hyperplasia, prostate cancer, hypercalcemia and nephrocalcinosis, and heart and coronary artery disease.
- Drug interactions: 69 interactions are recorded.
- Carfilzomib is rated Major.
- Moderate interactions include the corticosteroids hydrocortisone, dexamethasone, betamethasone, triamcinolone and budesonide. Others include cyclosporine, chlorpropamide, clofarabine, cannabidiol and asparaginase products.
- General class concerns: anabolic-androgenic steroids are associated with liver toxicity and muscle injury, and they are contraindicated in pregnancy because of fetal virilization. Package insert warnings were not available for this report, so please consult the insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there are no clinical trials or publications for this disease, so the evidence level is L5. The only conceivable mechanism is speculative and may worsen the disease, and the safety profile of this drug class is unfavorable.
To proceed, the following is needed:
- Mechanism-of-action data for stanozolol.
- Preclinical evidence on how stanozolol affects expression, folding and polymerization of the relevant serpin.
- Package insert warnings and contraindications from the Indian licences.
- A risk assessment for liver toxicity, given the disease’s liver involvement.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.